• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.

作者信息

Florido Roberta, Smith Karen L, Cuomo Kimberly K, Russell Stuart D

机构信息

Division of Cardiology, Johns Hopkins University, Baltimore, MD

Breast and Ovarian Cancer Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.

出版信息

J Am Heart Assoc. 2017 Sep 22;6(9):e006915. doi: 10.1161/JAHA.117.006915.

DOI:10.1161/JAHA.117.006915
PMID:28939718
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5634312/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c21/5634312/7d37e6ec0992/JAH3-6-e006915-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c21/5634312/7d37e6ec0992/JAH3-6-e006915-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c21/5634312/7d37e6ec0992/JAH3-6-e006915-g001.jpg

相似文献

1
Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.人表皮生长因子受体2（HER2）靶向治疗所致心脏毒性
J Am Heart Assoc. 2017 Sep 22;6(9):e006915. doi: 10.1161/JAHA.117.006915.
2
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.曲妥珠单抗用于临床实践中HER2阳性转移性乳腺癌的治疗：心脏毒性与总生存期
Eur J Cancer. 2016 Jan;52:41-9. doi: 10.1016/j.ejca.2015.09.012. Epub 2015 Nov 27.
3
The Evolving Landscape of HER2 Targeting in Breast Cancer.HER2 靶向治疗在乳腺癌中的不断发展。
JAMA Oncol. 2015 Nov;1(8):1154-61. doi: 10.1001/jamaoncol.2015.2286.
4
Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.评估曲妥珠单抗治疗人表皮生长因子受体 2 阳性乳腺癌。
Histol Histopathol. 2020 Oct;35(10):1059-1075. doi: 10.14670/HH-18-221. Epub 2020 Apr 23.
5
Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.信号转导治疗中的心脏毒性：erbB2抗体与心脏
Semin Oncol. 2001 Oct;28(5 Suppl 16):18-26. doi: 10.1016/s0093-7754(01)90278-7.
6
Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.新型 HER2 靶向疗法在乳腺癌治疗中的心血管毒性。
Curr Oncol Rep. 2021 Aug 27;23(11):128. doi: 10.1007/s11912-021-01114-x.
7
Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.用于乳腺癌的新辅助曲妥珠单抗治疗。最好坚持使用已证实有效的治疗方法。
Prescrire Int. 2013 Feb;22(135):39.
8
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.SAFE-HEaRt：一项关于HER2阳性乳腺癌且左心室功能降低患者中HER2靶向治疗心脏安全性的初步研究的原理与设计。
Oncologist. 2017 May;22(5):518-525. doi: 10.1634/theoncologist.2016-0412. Epub 2017 Mar 17.
9
Neratinib (Nerlynx) for HER2-positive breast cancer.来那替尼（Nerlynx）用于治疗HER2阳性乳腺癌。
Med Lett Drugs Ther. 2018 Jan 29;60(1539):23.
10
Controversies in the use of adjuvant trastuzumab (Herceptin).辅助性曲妥珠单抗（赫赛汀）使用中的争议。
J Br Menopause Soc. 2006 Dec;12(4):172-4. doi: 10.1258/136218006779160517.

引用本文的文献

1
Cardiotoxic Effects of HER2-Targeted Therapies: Insights From a Retrospective Study at a Romanian Oncology Center.HER2靶向治疗的心脏毒性作用：来自罗马尼亚肿瘤中心一项回顾性研究的见解
Cureus. 2025 Apr 25;17(4):e83012. doi: 10.7759/cureus.83012. eCollection 2025 Apr.
2
Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer.奥希替尼治疗肺癌后的心脏事件及动态超声心动图和心电图变化
Front Cardiovasc Med. 2024 Dec 16;11:1485033. doi: 10.3389/fcvm.2024.1485033. eCollection 2024.
3
Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.

本文引用的文献

1
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.早期HER2阳性乳腺癌的辅助性帕妥珠单抗和曲妥珠单抗治疗
N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5.
2
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.SAFE-HEaRt：一项关于HER2阳性乳腺癌且左心室功能降低患者中HER2靶向治疗心脏安全性的初步研究的原理与设计。
Oncologist. 2017 May;22(5):518-525. doi: 10.1634/theoncologist.2016-0412. Epub 2017 Mar 17.
3
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
使用奥希替尼治疗的表皮生长因子受体（EGFR）突变型非小细胞肺癌患者的心脏事件与生存情况
JAMA Netw Open. 2024 Dec 2;7(12):e2448364. doi: 10.1001/jamanetworkopen.2024.48364.
4
Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer.心血管疾病与癌症之间的常见生物学过程及相互串扰机制
Front Oncol. 2024 Nov 20;14:1453090. doi: 10.3389/fonc.2024.1453090. eCollection 2024.
5
The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy.肿瘤靶点表达水平在癌症免疫治疗中对IgA介导的细胞毒性的相关性。
Cancer Immunol Immunother. 2024 Oct 3;73(12):238. doi: 10.1007/s00262-024-03824-0.
6
Fibroblast growth factor 20 ameliorates cardiac hypertrophy via activation ErbB2.成纤维细胞生长因子20通过激活ErbB2改善心脏肥大。
Heliyon. 2024 Aug 30;10(17):e37085. doi: 10.1016/j.heliyon.2024.e37085. eCollection 2024 Sep 15.
7
DARPin-fused T cell engager for adenovirus-mediated cancer therapy.用于腺病毒介导癌症治疗的串联亲和素融合型T细胞衔接器
Mol Ther Oncol. 2024 May 29;32(3):200821. doi: 10.1016/j.omton.2024.200821. eCollection 2024 Sep 19.
8
Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations.应对癌症治疗引起的心脏毒性：从病理生理学到治疗创新
Adv Drug Deliv Rev. 2024 Aug;211:115361. doi: 10.1016/j.addr.2024.115361. Epub 2024 Jun 18.
9
Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain.曲妥珠单抗相关心脏功能障碍的特征：左心室整体纵向应变以外的变形分析。
Front Cardiovasc Med. 2024 Jan 19;11:1291180. doi: 10.3389/fcvm.2024.1291180. eCollection 2024.
10
Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers.各种癌症中人类表皮生长因子受体 2（HER2）基因的分子靶向治疗。
Int J Mol Sci. 2024 Jan 15;25(2):1064. doi: 10.3390/ijms25021064.
肌钙蛋白 I 和 T 及脑钠肽 N 端前体在监测早期人表皮生长因子受体 2 阳性乳腺癌接受曲妥珠单抗治疗患者心脏安全性中的作用：赫赛汀辅助研究心脏标志物子研究。
J Clin Oncol. 2017 Mar 10;35(8):878-884. doi: 10.1200/JCO.2015.65.7916. Epub 2016 Oct 23.
4
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.成人癌症幸存者心功能障碍的预防和监测：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2017 Mar 10;35(8):893-911. doi: 10.1200/JCO.2016.70.5400. Epub 2016 Dec 5.
5
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.多学科方法在心血管肿瘤学研究中的新型治疗方法（MANTICORE 101-乳腺）：预防曲妥珠单抗相关心脏毒性的随机试验。
J Clin Oncol. 2017 Mar 10;35(8):870-877. doi: 10.1200/JCO.2016.68.7830. Epub 2016 Nov 28.
6
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).2016年欧洲心脏病学会（ESC）实践指南委员会主持制定的关于癌症治疗与心血管毒性的立场文件：欧洲心脏病学会（ESC）癌症治疗与心血管毒性特别工作组。
Eur Heart J. 2016 Sep 21;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211. Epub 2016 Aug 26.
7
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).2016年欧洲心脏病学会（ESC）实践指南委员会主持制定的关于癌症治疗与心血管毒性的立场文件：欧洲心脏病学会（ESC）癌症治疗与心血管毒性特别工作组。
Eur J Heart Fail. 2017 Jan;19(1):9-42. doi: 10.1002/ejhf.654. Epub 2016 Aug 27.
8
Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.肥胖作为乳腺癌中蒽环类药物和曲妥珠单抗心脏毒性的危险因素：一项系统评价和荟萃分析
J Clin Oncol. 2016 Sep 10;34(26):3157-65. doi: 10.1200/JCO.2016.67.4846. Epub 2016 Jul 25.
9
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.坎地沙坦抑制血管紧张素Ⅱ受体预防早期乳腺癌患者曲妥珠单抗相关心脏毒性的随机临床试验。
JAMA Oncol. 2016 Aug 1;2(8):1030-7. doi: 10.1001/jamaoncol.2016.1726.
10
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.加拿大心血管学会癌症治疗相关心血管并发症的评估与管理指南。
Can J Cardiol. 2016 Jul;32(7):831-41. doi: 10.1016/j.cjca.2016.02.078. Epub 2016 Apr 7.